Table 1.
Baseline characteristics of pregnant women and children.
| Pregnant Women | Recruited (n = 166) | Included for analyses (n = 58) |
| Age, (years) | ||
| Mean (SD) | 26·4 (2·3) | 26·4 (2·6) |
| Median (IQR) | 27·0 (25·0–28·0) | 27·0 (26·0–28·0) |
| Gestational age at enrolment, (weeks) | ||
| Mean (SD) | 11·5 (1·5) | 11·6 (1·7) |
| Median (IQR) | 12·0 (10·4 –12·5) | 12·2 (10·2 – 12·5) |
| Ethnicity, n (%)a | ||
| Caucasian | 130 (77·8) | 46 (79·3) |
| Other | 35 (21·0) | 12 (20·7) |
| Vaginal HPV-DNA status, n (%) | ||
| Negative | 92 (55·4) | – |
| LR-HPV only | 19 (11·5) | 16 (27·6) |
| HR-HPV | 55 (33·1) | 42 (72·4) |
| HPV number of types, n (%) | ||
| None | 92 (55·4) | – |
| 1 type | 37 (22·3) | 31 (53·5) |
| >1 type | 37 (22·3) | 27 (46·5) |
| Vaccinated against HPV, n (%) | ||
| No | 156 (94·0) | 54 (93·1) |
| Yes | 10 (6·0) | 4 (6·9) |
| Anti-HPV6, (MFI)* | ||
| Mean (SD) | 2745·4 (4789·6) | 3199·7 (5296·0) |
| Median (IQR) | 416·5 (105·0–2635·0) | 461·5 (136·0–4323·0) |
| Anti-HPV11, (MFI)* | ||
| Mean (SD) | 1830·2 (4312·1) | 2211·8 (4803·6) |
| Median (IQR) | 356·0 (140·0–1316·0) | 559·0 (207·0–2174·0) |
| Anti-HPV16, (MFI)* | ||
| Mean (SD) | 2979·5 (5639·5) | 4317.1 (6542·4) |
| Median (IQR) | 0·0 (0·0–3258·0) | 333·0 (0·0–7317·0) |
| Anti-HPV18, (MFI)* | ||
| Mean (SD) | 1552·0 (3892·2) | 2900·6 (5125·8) |
| Median (IQR) | 0·0 (0·0–403·0) | 104 (0·0–3690·0) |
| Children born to HPV-positive women | Live births (n = 62) | Included for analyses (n = 58) |
| Gestational age at birth, (weeks) | ||
| Mean (SD) | 39·4 (1·5) | 39·3 (1·5) |
| Median (IQR) | 39·6 (38·9–40·6) | 39·5 (38·7–40·3) |
| Birth weight, (grams) | ||
| Mean (SD) | 3320·0 (462·0) | 3294·0 (457·0) |
| Median (IQR) | 3325·0 (3043·0–3640·0) | 3283·0 (3020·0–3635·0) |
| Sex, n (%) | ||
| Male | 29 (46·8) | 27 (46·5) |
| Female | 33 (53·2) | 31 (53·5) |
| Anti-HPV6, (MFI at birth)* | ||
| Mean (SD) | – | 2753·0 (4926·3) |
| Median (IQR) | – | 365·5 (166·0–2752·0) |
| Anti-HPV11, (MFI at birth)* | ||
| Mean (SD) | – | 1883·3 (4703·0) |
| Median (IQR) | – | 332·0 (73·0–1127·0) |
| Anti-HPV16, (MFI at birth)* | ||
| Mean (SD) | – | 3804·7 (6318·1) |
| Median (IQR) | – | 0·0 (0·0–5117·0) |
| Anti-HPV18, (MFI at birth)* | ||
| Mean (SD) | – | 2188·8 (4421·1) |
| Median (IQR) | – | 0·0 (0·0–1664·0) |
a
Missing data excluded
⁎
Mean fluorescence intensity (MFI) values from dried blood spot (DBS) samples.
n, number; SD, standard deviation; IQR, interquartile range; LR-HPV, low risk human papillomavirus; HR-HPV, high risk human papillomavirus; MFI, mean fluorescence intensity; DBS, dried blood spot.